Bayer's $10.5 Billion Effort to Resolve Roundup Lawsuits

Entertainment National Sports Markets Business & Economy Lifestyle World Astrology & Religion Technology Education & Jobs Auto Politics Viral Opinions

Loading more articles...

Bayer to Settle Roundup Cases for $10.5 Billion Amid Cancer Lawsuits

Bayer to Settle Roundup Cases for $10.5 Billion Amid Cancer Lawsuits

C

CNBC TV18•17-02-2026, 22:32

Bayer to Settle Roundup Cases for $10.5 Billion Amid Cancer Lawsuits

•Bayer AG plans a $10.5 billion settlement to resolve current and future cancer lawsuits related to its Roundup weedkiller.
•The settlement includes $7.5 billion for a class-action in Missouri, covering existing and potential claims over 20 years.
•An additional $3 billion is allocated to settle existing US cases where users blame Roundup for non-Hodgkin lymphoma.
•Bayer's shares rose 7.9% in Frankfurt following the news, marking the biggest gain in a month.
•The company has faced extensive litigation since acquiring Monsanto, with over $10 billion already paid in verdicts and settlements.

Read Full Article on Cnbc in English

✦

More like this

✦

More like this

Late sex offender Jeffrey Epstein. (Image: Reuters)

Epstein Estate to Pay $35 Million Settlement to Victims in New Lawsuit

Epstein Estate's $35M Settlement with Accusers Gets Preliminary Judge Approval

Epstein Estate's $35M Settlement with Accusers Gets Preliminary Judge Approval

Natco Pharma | Announces the launch of Pomalidomide Capsules in the US market used in the treatment of Adult patients with Multiple Myeloma. These capsules had estimated sales of $3.2 billion in the US for the 12 months that ended in September 2025.

Natco Pharma shares gain 3% on US launch of multiple myeloma drug

Cohance Lifesciences Shares Soar 10% After ₹216 Crore Block Deal

Cohance Lifesciences Shares Soar 10% After ₹216 Crore Block Deal

Eternal, Swiggy shares rise

Delivery Tech Stocks Soar: Eternal, Swiggy Hit Multi-Week Highs on AI, MF Holdings

The BMC plans to start 25 more Aapla Dawakhana and three physiotherapy centres in the next financial year.

Zydus Lifesciences settles Mirabegron patent dispute with Astellas for $120 mn